

FACTSHEET

MYELOMA PATIENTS EUROPE

ELOTUZUMAB (Empliciti®)

Edition: Myeloma Patients Europe (MPE) **Updated:** November 2020

Myeloma Patients Europe AISBL Avenue Louise 143/4 1050 Brussels Belgium www.mpeurope.org info@mpeurope.org



FACTSHEET

MYELOMA PATIENTS EUROPE

Myeloma Patients Europe (MPE) has developed a series of factsheets for patients and patient advocates, providing an overview of available treatment options for myeloma and covering some relevant topics related to the disease.

The factsheets cover important issues around the treatment, so that patients can feel safe and ask specific questions to their doctor.

For each of the available therapies, the following topics will be addressed:

- What is myeloma?
- What is the particular treatment?
- How does the treatment work?
- What are the benefits?
- What are the side effects?
- Who should not receive the treatment?
- How and when is the treatment given?

Access the following factsheets on:

- Amyloidosis
- Belantamab mafodotin
- Bortezomih
- Carfilzomih
- Daratumumab
- Flotuzumab
- Ixazomib
- I enalidomide
- Panobinostat
- Pomalidomide
- Thalidomide
- Stem cell transplant

Myeloma treatment is constantly evolving and the factsheets will be updated regularly to reflect the latest developments.


What is myeloma?

Myeloma is a rare cancer of the bone marrow. It is due to the formation of abnormal plasma cells, also called myeloma cells, which divide uncontrollably. Usually, plasma cells help the body to fight infections by making antibodies that recognise and attack germs. Myeloma affects multiple places in the body (this is why it is sometimes referred to as 'multiple myeloma') where bone marrow is normally active, such as the bones of the spine, pelvis, rib cage and the areas around the shoulders and hips.

Myeloma causes pain, anaemia (low red blood cells), fatigue, fractures, recurring infections, bruising and high blood calcium (hypercalcaemia). These symptoms require treatment; if the disease responds to therapy, there could be periods of time where symptoms subside and may not require any treatment. This cycle of remission and recurrence (relapse) often occurs several times. Many patients, particularly in relapse setting, will be on treatment for a long period of time to ensure that their myeloma is kept at bay.

Treatment may involve taking a combination of drugs that have been found to be more effective than single drugs. Myeloma generally cannot be cured, but survival rates are increasing in myeloma, due to the availability of new treatment and many patients are able to enjoy a good quality of life. A number of other new treatments have recently been approved or are under consideration for use following relapse, or for refractory myeloma.

Myeloma



What is Elotuzumab (Empliciti®)?

Elotuzumab is a monoclonal antibody. It was approved in Europe in 2016 for use in combination with lenalidomide (Revlimid) and dexamethasone (ERd).

Elotuzumab is also indicated in combination with pomalidomide (Imnovid) and dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies including lenalidomide (Revlimid) and a proteasome inhibitor and have demonstrated disease progression on the last therapy.

As multiple myeloma is considered a 'rare disease' because of the small number of patients with this disease, elotuzumab was granted 'orphan drug designation'* by the European Commission in 2016. An orphan drug designation is a status assigned to medicines developed for rare disease conditions that affect less than 5 patients per 10,000 inhabitants in the EU.

How does elotuzumab work?

Elotuzumab is a monoclonal antibody (a laboratory engineered antibody that mimics human antibodies) that specifically targets the SLAMF7 protein (also known as CS1) which is expressed on the surface of myeloma cells and natural killer cells (NK cells) of the immune system. Elotuzumab has a dual mechanism of action. By binding to the SLAMF7 protein on natural killer cells, this drug activates the immune system. It also targets SLAMF7 on myeloma cells, which tags them for recognition by natural killer cells. When a natural killer cell of the immune system is activated by elotuzamab, the natural killer cell then recognises the already tagged myeloma cell and induces cell death.

What are the benefits of elotuzumab?

A clinical trial, involving 646 patients, evaluated the combination of elotuzumab, lenalidomide, and low-dose dexamethasone as compared to lenalidomide and dexamethasone alone in patients who had received one to three prior therapies and had progressed following their most recent therapy. Patients who took this new combination (elotuzumab, lenalidomide, and low-dose dexamethasone) had a 30% reduction of risk of disease progression or death compared to patients who

took only lenalidomide and dexamethasone. Patients receiving a combination treatment lived without their disease worsening for an average of 4.5 months longer than patients taking lenalidomide and dexamethasone alone (19.4 months vs. 14.9 months). These observed benefits were maintained over time. In addition, a higher percentage of patients taking this combination treatment achieved a partial or complete response as compared to those taking lenalidomide and dexamethasone alone (overall response rate of 79% vs. 66%).

How and when is elotuzumab given?

Elotuzumab is available as a powder to be made up into a solution. It is given as an intravenous (IV) infusion (drip) into a vein. The dose is 10 mg/kg of body weight. Treatment takes place in 28-day cycles. It is given along with oral lenalidomide and dexamethasone once a week for the first two cycles and every two weeks



after that time. Elotuzumab is given until the disease progresses or if there is unacceptable toxicity.

Patients are required to take the following oral medications to reduce the risk of infusion reaction before receiving elotuzumab:

- anti-inflammatory medicine (dexamethasone)
- antihistamines (e.g. diphenhydramine and ranitidine)
- a fever-reducing agent (e.g. acetaminophen, paracetamol)

What are the side effects?

The most common side effects seen with elotuzumab in combination with lenalidomide and low-dose dexamethasone (which may affect more than 1 in 10 people)¹ are infusion reactions (with symptoms such as fever and chills) as well as:

- diarrhoea
- shingles (painful, blistering rash)
- cough
- numbness, weakness, tingling, or burning pain in the arms or legs
- sore throat or runny nose
- upper respiratory tract infection
- decreased appetite
- pneumonia (lung infection)
- colds
- low levels of white blood cells
- weight loss

The majority of side effects are mild or moderate, and the most serious is pneumonia.

Patients should contact their healthcare provider if they experience signs and symptoms of infusion reactions including fever, chills, rash or breathing problems within 24 hours of infusion.

References

- The Multiple Myeloma Research Foundation (MMRF). https://www. themmrf.org/multiple-myeloma-knowledge-center/myeloma-drugs-guide/ empliciti-elotuzumab/
- Food and Drug Administration. Approved Drugs. http://www.fda.gov/ Drugs/InformationOnDrugs/ApprovedDrugs/ucm474719.htm
- Manufacturer's product information http://www.empliciti.com/ and http:// packageinserts.bms.com/pi/pi_empliciti.pdf
- 4. European Medicines Agency. Empliciti (elotuzumab) European public assessment report (EPAR) – last updated 09/2019: https://www.ema. europa.eu/en/documents/overview/empliciti-epar-medicine-overview_en.pdf
- Lonial S et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med 2015: 373:621-631.





© Myeloma Patients Europe (MPE)

MPE is a network of European myeloma patient organisations. It supports national patient organisations to improve treatment and access for patients in their countries and helps inform and raise awareness on a European level through its educational programmes. Please note, this information does not replace the information provided by your doctor. If there is anything that is not clear to you, please always ask your clinical team.



© Myeloma Patients Europe (MPE)

Myeloma Patients Europe







